Research Papers:

Potential options for managing LOX+ ER- breast cancer patients

Yong Han, Shenyi Lian, Xingran Cui, Kexin Meng, Balázs Győrffy, Tao Jin and Dongsheng Huang _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:32893-32901. https://doi.org/10.18632/oncotarget.9073

Metrics: PDF 1782 views  |   HTML 2481 views  |   ?  


Yong Han1,*, Shenyi Lian2,*, Xingran Cui3, Kexin Meng4, Balázs Győrffy5,6, Tao Jin7, Dongsheng Huang1

1Clinical Research Institute, Zhejiang Provincial People’s Hospital, Hangzhou, China

2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital and Institute, Beijing, China

3Division of Interdisciplinary Medicine and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA

4Department of Thyroid Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China

5Momentum Cancer Biomarker Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary

6Second Department of Pediatrics, Semmelweis University, Budapest, Hungary

7Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China

*These authors contributed equally to this work

Correspondence to:

Tao Jin, email: [email protected]

Dongsheng Huang, email: [email protected]

Keywords: LOX, estrogen recepter, EMT, chemoresistance, bisphosphonates

Received: September 01, 2015     Accepted: April 11, 2016     Published: April 28, 2016


Overexpression of lysyl oxidase (LOX) is often observed in estrogen receptor negative (ER–) breast cancer patients with bone metastasis. In the present bioinformatics study, we observed that LOX is a prognostic factor for poor progression free survival in patients with ER– breast cancer. LOX overexpression was positively correlated with resistance to radiation, doxorubin and mitoxantrone, but negatively correlated with resistance to bisphosphonate, PARP1 inhibitors, cisplatin, trabectedin and gemcitabine. LOX overexpression was also associated with EMT and stemness of cancer cells, which leads to chemotherapeutic resistance and poor outcome in ER– patients. Although we suggest several therapeutic interventions that may help in the management of LOX+ ER– breast cancer patients, experiments to validate the function of LOX in ER– breast cancer are still needed.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9073